	TH AND HUMAN SERVICES G ADMINISTRATION	
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION	
19701 Fairchild	09/10/2014 - 10/09/2014*	
	FEI NUMBER	
Irvine, CA 92612 (949) 608-2900 Fax: (949) 608-4417	3005144312	
Industry Information: www.fda.gov/oc/indu	stry	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED		
TO: Tenille D. Davis, Pharm D., RPh, Pha	rmacy Manager	
FIRM NAME	STREET ADDRESS	
Civic Center Pharmacy	7331 E Osborn Dr Ste 208	
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED	
Scottsdale, AZ 85251-6420	Producer of Sterile Drug Products	

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

Environmental Monitoring of the firm's ISO 5 environments and ISO 7 Cleanroom environments used to produce sterile drug products is not conducted during active processing and does not represent actual conditions, for example:

- a) Your firm does not routinely conduct viable particulate air monitoring during actual aseptic processing of drug products in the ISO 5 hoods. Viable particulate air monitoring is only conducted every months by an outside contractor.
- b) Your firm does not routinely conduct viable particulate air monitoring of the ISO 7 cleanroom during active processing of drug products. The ISO 5 Laminar air flow hoods are located within the ISO 7 cleanroom. Viable particulate air monitoring is only conducted every months by an outside contractor.
- c) Your firm does not routinely conduct non-viable particulate air monitoring during actual aseptic processing of drug products in the ISO 5 hoods. Non-viable particulate air monitoring is only conducted every months by an outside contractor.
- d) Your firm does not routinely conduct non-viable particuate air monitoring of the ISO 7 environments during active processing of drug products. The ISO 5 Laminar air flow hoods are located within the ISO 7 cleanroom. Non-viable particulate air monitoring is only conducted every months by an outside contractor.
- e) Your firm does not actively monitor cleanroom pressure differentials during aseptic processing of drug products.

 Differential pressures of the ISO 7 Anteroom, ISO 7 Cleanroom and other areas are (b) (4) read and recorded (b) (4) per day in the (b) (4) to the start of productsion under static condition. There is no further monitoring of the cleanroom pressure differentials either manually or by electronic devices during production.
- f) Your firm does not conduct adequate surface environmental monitoring (work surfaces, floors, walls, ceilings) that represent actual conditions. It was explained that surface environmental monitoring is conducted on a (b) (4) basis and samples are collected (b) (4)

FORM FDA 483 (09/08)		PREVIOU	S EDITION OBSOLETE	INSPECTION	AL OBSERVATIONS		PAGE 1 OF 3 PAGES
SEE REVERSE OF THIS PAGE	Joey	7 V.	Quitania,	Investigator	Huitama	10/09/14	10/09/2014
	EMPLOYEE(S) SIGNATURE					DATE ISSUED	

		T OF HEALTH AND HUMAN SERVICE	S
DISTRICT ADDRESS AND PHON		DOD AND DRUG ADMINISTRATION DATE(S) OF	FINSPECTION
19701 Fairchi	ld		0/2014 - 10/09/2014*
Irvine, CA 9	2612 0 Fax: (949) 608-4417		
		on: www.fda.gov/oc/industry	
TO: Tenille	D. Davis, Pharm D., R	Ph, Pharmacy Manager	
Civic Center	Pharmacy	7331 E Osborn Dr Ste 208 TYPE ESTABLISHMENT INSPECTED	
Scottsdale, A	Z 85251-6420	Producer of Ster	ile Drug Products
production		onnel monitoring (fingertips, hands, s that process drug products intended ored every months.	
Specifically, a) There are Serum Via establishe	established written procedures. als and Stoppers", eff 12/18/13 a d or well designed to prevent mi	However, SOP 8.030, Vers 1.0, "Ste and your firm's process for handling s crobiological contamination." r procedure for removing sterilized v ISO 8 (Class 100,000) Compounding	erilization and Depyrogenation of sterilized vials has not been well rials from the (b) (4)
b) Your firm contamina	's process for aseptically filling ation.	ons on the handling of sterilized vials and stoppering vials has not been we r procedure for stoppering asepticall	Il designed to prevent microbiological
11			
On 09/11/ were bein	14, I also observed the filling pr I observe	ocess of vials. The process is (b) (4	er over unstoppered vials as the vials
	ole, on 09/11/14, the(b) (4)	re not always disinfected before intro containing stoppers was not wipe	oduction. d down as it was passed from the (b) (4)
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Joey V. Quitania, In	vestigator JVF	10/09/2014
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 2 OF 3 PAGES

DI	EPARTMENT OF HEALTH AND HUM FOOD AND DRUG ADMINISTRAT			
DISTRICT ADDRESS AND PHONE NUMBER 19701 Fairchild	FOOD AND DRUG ADMINISTRA	DATE(S) OF INSPECTION 09/10/2014 - 10/09/2014*		
Irvine, CA 92612		FEI NUMBER		
(949) 608-2900 Fax: (949) 6		3005144312		
Industry Information: WWW.f	da.gov/oc/industry			
TO: Tenille D. Davis, Phar	m D., RPh, Pharmacy Mar	nager		
Civic Center Pharmacy				
Scottsdale, AZ 85251-6420	Producer	of Sterile Drug Products		
	emonstrate the air flow is smooth, l	ally process drug products does not include laminar, and without turbulence under dyna		
EMP OYEE(S) SIGNATURE		DATE ISSUE	lo .	
SEE REVERSE Joey V. Quita OF THIS PAGE	nia, Investigator	nitania 10/09/14 10/09	/2014	
FORM FDA 483 (09/08) PREVIOUS EDITION OR	SOLETE INSPECTIONAL OB	SERVATIONS PAGE 30	OF 3 PAGES	